Trinity Expands US Business
Dublin - Irish diagnostics specialist Trinity Biotech plc expands its activities in the US. In mid-April the company acquired the distributor for diagnostic tools, Adaltis US Inc. for $3.5 million in cash. As part of the transaction, Trinity obtained exclusive distribution rights to Adaltis' open-end microplate analytical instrumentation in the US and non-exclusive distribution rights in the rest of the world, except China.
“The acquisition of Adaltis US is a strategic move for Trinity and is designed to enhance our infectious disease product offering. Crucially the acquisition gives Trinity access to the existing installed base of instruments in the US and provides an opportunity to place its own reagents on this installed base of instruments. “We believe the Adaltis range of instruments provides us with access to the best microtitre plate instrument offering available on the market”, said Ronan O'Caoimh, CEO of Trinity Biotech. The company expects first profits from the acquisition in 2005.